FINE yields 0.98% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, FINE + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FINE + JNJ for your $10,000?
FINE aims to replicate an index of European companies generating at least 50% of their revenues from luxury-related business operations. The index is focused on companies headquartered in developed Europe, such as Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, or the United Kingdom. Eligible securities must meet certain size and trading volume requirements. After this basic screen, a proprietary natural language processing algo screens publicly available information such as financial news and business profiles to identify and score companies involved in the investment theme. These may include firms involved in the design, manufacturing, or sale of luxury and designer accessories, high-end or designer clothing and beauty products, exclusive and luxurious automobiles and boats, luxury hotels, resorts, and spas. The 25 highest ranking companies are included in the index and are given an equal weighting. The index is reconstituted annually and rebalanced semi-annually.
Full FINE Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.